A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

Trastuzumab is established as treatment of HER2(high) metastatic breast cancers but many limitations impair its efficacy. Here, we report the design of a Fab-like bispecific antibody (HER2bsFab) that displays a moderate affinity for HER2 and a unique, specific and high affinity for FcγRIII. In vitro...

Descripción completa

Detalles Bibliográficos
Autores principales: Turini, Marc, Chames, Patrick, Bruhns, Pierre, Baty, Daniel, Kerfelec, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170649/
https://www.ncbi.nlm.nih.gov/pubmed/24979648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170649/
https://www.ncbi.nlm.nih.gov/pubmed/24979648

Ejemplares similares